Sirnaomics said this week that it has signed a deal with an undisclosed Chinese pharmaceutical company to co-develop an siRNA-based drug for scarless wound healing.
The drug, STP705, uses a polymeric nanoparticle to enhance topical delivery of siRNAs targeting the TGF-beta 1 and Cox-2 genes to open wounds, Sirnaomics said.
The new alliance "provides financial resources and local capabilities allowing acceleration through the clinical study and regulatory process in China," the company added.
The arrangement, which includes "licensing, funding, and market-sharing structures," is limited to the greater China area, including Hong Kong, Macau, and Taiwan. Additional terms were not disclosed.